Bangladesh · Delayed Price · Currency is BDT Advent Pharma Statistics
Total Valuation
Advent Pharma has a market cap or net worth of BDT 1.30 billion. The enterprise value is 1.38 billion.
| Market Cap | 1.30B |
| Enterprise Value | 1.38B |
Important Dates
The last earnings date was Thursday, April 30, 2026.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Nov 23, 2025 |
Share Statistics
Advent Pharma has 93.13 million shares outstanding. The number of shares has decreased by -0.62% in one year.
| Current Share Class | 93.13M |
| Shares Outstanding | 93.13M |
| Shares Change (YoY) | -0.62% |
| Shares Change (QoQ) | -0.88% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 26.98.
| PE Ratio | 26.98 |
| Forward PE | n/a |
| PS Ratio | 2.85 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.84 |
| P/FCF Ratio | 5,175.75 |
| P/OCF Ratio | 30.57 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.25, with an EV/FCF ratio of 5,480.42.
| EV / Earnings | 28.74 |
| EV / Sales | 3.01 |
| EV / EBITDA | 10.25 |
| EV / EBIT | 19.27 |
| EV / FCF | 5,480.42 |
Financial Position
The company has a current ratio of 1.81, with a Debt / Equity ratio of 0.05.
| Current Ratio | 1.81 |
| Quick Ratio | 1.27 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.58 |
| Debt / FCF | 308.23 |
| Interest Coverage | 7.56 |
Financial Efficiency
Return on equity (ROE) is 3.13% and return on invested capital (ROIC) is 3.41%.
| Return on Equity (ROE) | 3.13% |
| Return on Assets (ROA) | 2.30% |
| Return on Invested Capital (ROIC) | 3.41% |
| Return on Capital Employed (ROCE) | 4.03% |
| Weighted Average Cost of Capital (WACC) | 6.10% |
| Revenue Per Employee | 1.45M |
| Profits Per Employee | 151,517 |
| Employee Count | 317 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 4.17 |
Taxes
In the past 12 months, Advent Pharma has paid 13.98 million in taxes.
| Income Tax | 13.98M |
| Effective Tax Rate | 22.55% |
Stock Price Statistics
The stock price has increased by +4.48% in the last 52 weeks. The beta is 0.30, so Advent Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +4.48% |
| 50-Day Moving Average | 13.80 |
| 200-Day Moving Average | 14.21 |
| Relative Strength Index (RSI) | 55.04 |
| Average Volume (20 Days) | 261,813 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Advent Pharma had revenue of BDT 458.15 million and earned 48.03 million in profits. Earnings per share was 0.52.
| Revenue | 458.15M |
| Gross Profit | 139.05M |
| Operating Income | 71.64M |
| Pretax Income | 62.01M |
| Net Income | 48.03M |
| EBITDA | 134.17M |
| EBIT | 71.64M |
| Earnings Per Share (EPS) | 0.52 |
Balance Sheet
The company has 896,831 in cash and 77.65 million in debt, with a net cash position of -76.75 million or -0.82 per share.
| Cash & Cash Equivalents | 896,831 |
| Total Debt | 77.65M |
| Net Cash | -76.75M |
| Net Cash Per Share | -0.82 |
| Equity (Book Value) | 1.56B |
| Book Value Per Share | 17.69 |
| Working Capital | 163.39M |
Cash Flow
In the last 12 months, operating cash flow was 42.65 million and capital expenditures -42.40 million, giving a free cash flow of 251,917.
| Operating Cash Flow | 42.65M |
| Capital Expenditures | -42.40M |
| Depreciation & Amortization | 62.53M |
| Net Borrowing | 1.38M |
| Free Cash Flow | 251,917 |
| FCF Per Share | 0.00 |
Margins
Gross margin is 30.35%, with operating and profit margins of 15.64% and 10.48%.
| Gross Margin | 30.35% |
| Operating Margin | 15.64% |
| Pretax Margin | 13.54% |
| Profit Margin | 10.48% |
| EBITDA Margin | 29.29% |
| EBIT Margin | 15.64% |
| FCF Margin | 0.05% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.36%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.36% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.29% |
| Buyback Yield | 0.62% |
| Shareholder Yield | 0.98% |
| Earnings Yield | 3.68% |
| FCF Yield | 0.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 28, 2022. It was a forward split with a ratio of 1.02.
| Last Split Date | Feb 28, 2022 |
| Split Type | Forward |
| Split Ratio | 1.02 |
Scores
Advent Pharma has an Altman Z-Score of 2.78 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.78 |
| Piotroski F-Score | 5 |